World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
153
Citations
97714
World Ranking
1034
National Ranking
590

Michael Heinrich publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Heinrich sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 981 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Heinrich D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Heinrich sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 153 D-Index — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Heinrich is affiliated with Oregon Health & Science University in the United States and specializes in medical research with a primary focus on gastrointestinal tumors and related disorders. Their extensive publication record highlights a career dedicated to advancing understanding and treatment in the fields of medicine, particularly within gastroenterology and oncology.

The main fields of study for this researcher encompass Medicine, with detailed work in subfields including Pulmonary and Respiratory Medicine, Gastroenterology, Hematology, Surgery, and Genetics. Their research covers various aspects of gastrointestinal tumor research and treatment, gastric cancer management and outcomes, gastrointestinal disorders and treatments, chronic myeloid leukemia treatments, sarcoma diagnosis and treatment, chronic lymphocytic leukemia research, and platelet disorders and treatments.

Michael Heinrich's frequent coauthors include Suzanne George, Sebastian Bauer, Robin L. Jones, Margaret von Mehren, and César Serrano, reflecting ongoing collaborations within their research network.

Their common publication venues are diverse but centered primarily in clinical oncology and cancer research, featuring notable contributions to:

  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Annals of Oncology
  • Blood
  • Clinical Cancer Research

Notable recent papers authored or coauthored by Michael Heinrich include:

  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial, 2020, The Lancet Oncology
  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, 2023, Journal of Clinical Oncology
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial, 2021, European Journal of Cancer
  • Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study, 2021, Journal of Clinical Oncology

The scope of Michael Heinrich's work reflects a systematic approach to understanding and treating gastrointestinal stromal tumors and related cancer types. Through clinical trials and translational research, they contribute to the evolving standards of care within oncology, particularly focusing on targeted therapies for specific genetic mutations.

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Biology of gastrointestinal stromal tumors.

    Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich

  • Medicinal plants in Mexico: healers' consensus and cultural importance.

    Michael Heinrich;Anita Ankli;Barbara Frei;Claudia Weimann

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

    Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia

  • Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

    Michael C. Heinrich;Diana J. Griffith;Brian J. Druker;Cecily L. Wait

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

    Anne Marie O'Farrell;Tinya J. Abrams;Helene A. Yuen;Theresa J. Ngai

  • PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

    Christopher L. Corless;Arin Schroeder;Diana Griffith;Ajia Town

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Hibiscus sabdariffa L. - A phytochemical and pharmacological review

    Inês Da-Costa-Rocha;Bernd Bonnlaender;Hartwig Sievers;Ivo Pischel

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • Gastrointestinal stromal tumours: origin and molecular oncology

    Christopher L. Corless;Christine M. Barnett;Michael C. Heinrich

  • Gastrointestinal stromal tumour

    Brian P Rubin;Michael C Heinrich;Michael C Heinrich;Christopher L Corless;Christopher L Corless

  • Clinical management of gastrointestinal stromal tumors : before and after STI-571

    Ronald P. Dematteo;Michael C. Heinrich;Wa'el M. El-Rifai;George Demetri

  • Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies

    Michael C. Heinrich;Charles D. Blanke;Brian J. Druker;Christopher L. Corless

Frequent Co-Authors

Christopher L. Corless
Christopher L. Corless Oregon Health & Science University
Brian J. Druker
Brian J. Druker Oregon Health & Science University
Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Suzanne George
Suzanne George Harvard University
Michael W. Deininger
Michael W. Deininger University of Utah
Otto Sticher
Otto Sticher ETH Zurich
Brian P. Rubin
Brian P. Rubin Cleveland Clinic
Heikki Joensuu
Heikki Joensuu University of Helsinki

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternate or supplementary pathways in healthcare can enhance your career options beyond traditional medical school. Many students are considering accredited online degrees, which offer both flexibility and affordability.

If your interests align with mental health, there are shortest post master's pmhnp online programs available to help you quickly become a Psychiatric Mental Health Nurse Practitioner. This can be a rewarding alternative for those who wish to provide mental healthcare.

Healthcare administration is another growing field. You can start by pursuing the cheapest online healthcare administration degree, and later advance with the cheapest online master degree in healthcare administration. These degrees prepare you for leadership roles in healthcare settings without clinical requirements.

For those seeking the highest nursing credentials, the best dnp programs online provide a pathway to advanced clinical practice and executive positions.

Online degrees make it easier than ever to join and excel in the healthcare industry while aligning your educational investment with your professional goals.

Best Scientists Citing Michael Heinrich

Trending Scientists

Recently Published Articles